Addressing Cardiovascular Events:

Educational Objectives

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin monotherapy in high-risk patients presenting with acute coronary syndrome

Biologic Basis For Lowering LDL-C

LDL Hypothesis Is Lowering the LDL Enough, Or Does the Agent Matter?

Determinants of Atherosclerosis

Study Design

IMPROVE-IT Study Goals

IMPROVE-IT Not a Placebo Study

IMPROVE-IT Ezetimibe/Simvastatin Reduces Risk of Cardiovascular Events

IMPROVE-IT Safety Data

Safety of Other LDL Lowering Treatments

Abstract Presented at ACC 2015

Hypothesis

Number of Primary End Point Events

Total Primary End Point Events

What we know about “Lower is Better”

Conclusions

Conclusions

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)